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Summary Anti-tumour responses with CCRG81010, M & B 39565, NSC 353451, 8-carbamoyl-3-(2-chloro-
ethyl)imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (Mitozolomide) in a panel of 4 murine colon tumours of
varying growth characteristics and chemosensitivity and a spontaneous murine lymphoma are similar to those
seen with standard nitrosoureas. The moderately well differentiated colon adenocarcinoma MAC 16 is non-
responsive to mitozolomide and methylCCNU. Responses in the other 4 lines studied are only achieved near
to maximum tolerated dose and at this level there is severe host toxicity. Haemopoietic toxicity is clearly
demonstrated by analysis of peripheral blood counts and by CFU-S assays and severe testicular and ovarian
toxicity was also seen at dose levels necessary to achieve anti-tumour effects. Using mitozolomide as an
example, the study has demonstrated the feasibility of conducting simple but thorough toxicity evaluation for
the determination of the therapeutic index. This approach would provide invaluable guidelines for the
selection for clinical trial of the most appropriate members of a series of new cytotoxic compounds.
The most disappointing area of anti-cancer drug develop-
ment is activity in common solid tumours which lags far
behind lymphomas and leukaemias. Most of the agents
which enter clinical trial have scant or no activity against
solid tumours of mice (Corbett et al., 1984; Double & Ball,
1975). One must conclude therefore that the criteria for
identifying new drugs for clinical development in the
National Cancer Institute (NCI) screens for 1970 to 1985 are
unsatisfactory for the detection of clinically useful drugs
against the common human cancers (Muggia, 1987). The
limited clinical activity observed amongst anti-cancer drugs is
likely to be a direct result of the methods used in their
selection. The most striking finding is the extent to which the
activity discovered amongst the drugs is confined to the
haematological malignancies. While this may represent
innate sensitivity of these tumours to cytotoxic agents it may
also be that the pre-clinical screening programmes of the
NCI, based heavily on the murine leukaemias, select new
agents active primarily in human leukaemia and lymphoma
(Marsoni et al., 1987). Furthermore a radical departure in
the screening programme in the NCI is now underway but
nevertheless carefully chosen transplantable mouse tumours
can (and should) have their place in the new strategies being
developed (Corbett et al., 1987).
Mitozolomide [CCRG 81010, M&B 39565, NSC 353451,
8-carbamoyl-3-(2-chloroethyl)imidazo [5,1-d]-1,2,3,5-tetrazin-
4(3H)-one] is a new anti-tumour agent possessing a novel
chemical structure (Stevens et al., 1984) with significant
activity against a wide range of murine tumours (Hickman et
al., 1982). Horgan & Tisdale (1984) proposed that the
cytotoxicity of mitozolomide is mediated via its breakdown
product, MCTIC (5-[3-(2-chloroethyl)triazen 1-yl]-imidazole-
4-carboxamide) by the formation of interstrand cross links
with DNA in a similar manner to that described for the
chloroethyl nitrosoureas (Gibson et al., 1984). The chloro-
ethyl nitrosoureas are extremely effective anti-cancer agents
in experimental tumour systems, but unfortunately their
clinical value is limited by their pronounced and delayed
toxicity especially to the bone marrow. Preliminary studies in
this laboratory (Double & Bibby, 1984) demonstrated
activity of mitozolomide against a panel of experimental
murine tumours that are generally poorly responsive to
standard agents. Responses seen were very similar to those
seen with methylCCNU. In view of the similarity in res-
ponses to those previously shown by the nitrosoureas the
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authors were concerned about the possible clinical outcome.
The phase I clinical trial of intravenous mitozolomide (New-
lands et al., 1985) demonstrated that nausea and vomiting
was dose related but not severe, the dose limiting toxic effect
was thrombocytopaenia at levels greater than 115 mgm-2
and recovery from this thrombocytopaenia was delayed up
to 8 weeks. Additional studies showed that when mitozolo-
mide was given orally to an older population, most patients
experienced thrombocytopaenia (Newlands et al., 1985).
Following a phase II trial in melanoma, lung and ovarian
cancer, Harding et al. (1987) concluded that clinical appli-
cation of mitozolomide, particularly in combinations, would
be difficult because of unpredictable and frequently cumula-
tive myelosuppression. The aims of this study were two-fold.
Firstly to establish the anti-tumour activity of mitozolomide
against a panel of transplantable adenocarcinomata of the
mouse colon (MAC series). These tumours have previously
been shown to be a good model of human disease in that
responses to standard agents are only seen close to maxi-
mum tolerated dose (Double & Ball, 1975) and are currently
extensively used by this laboratory as part of the pre-clinical
evaluation of new anti-cancer agents within the Screening
and Pharmacology Group of the EORTC. Activity against a
poorly responsive mouse lymphoma was also assessed.
Secondly, and in parallel, the study also examined the
haematological and reproductive toxicity. The object of this
arm of the study was to ascertain the feasibility of carrying
out minimal toxicity studies in conjunction with anti-tumour
activity determination in resistant tumours as part of secon-
dary pre-clinical evaluation of novel potential anti-cancer
agents.
Materials and methods
Animals
Pure strain NMRI mice aged 8-10 weeks from our inbred
colony were used. They were fed on CRM diet (Labsure,
UK) and water ad libitum.
Tumour system
The development of several adenocarcinomata of the large
bowel in NMRI mice from primary tumours induced by
prolonged administration of 1,2-dimethylhydrazine has been
described elsewhere (Double et al., 1975). BML1 is a spon-
taneous lymphoma, derived in this laboratory, which has
been serially passaged by intraperitoneal (i.p.) inoculation of
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a spleen cell suspension (1 x 106) for a period of 3 years.
BML1 cells were inoculated into male mice. The poorly
differentiated MAC 13 (Cowen et al., 1980) and MAC 16
(Bibby et al., 1987) tumours were transplanted into female
mice and the well-differentiated MAC26 tumours into male
mice, by subcutaneous (s.c.) implantation of tumour frag-
ments (- 1 x 2mm) in the flank. MAC 15A ascites tumours
(Double & deCastro, 1978) were transplanted into male mice
by i.p. inoculation of I x 106 tumour cells in 0.2 ml physiolo-
gical saline.
Test compounds
MethylCCNU (MeCCNU) was a gift from the National
Cancer Institute (NCI), USA; mitozolomide from Prof.
M.F.G. Stevens, University of Aston, UK; thioTEPA from
Lederle Laboratories, Gosport, Hants, UK; 5-FU from
Roche, Welwyn Garden City, UK; and cyclophosphamide
from the Boehringer Corporation, London, UK. ThioTEPA,
5-FU and cyclophosphamide were dissolved in 0.9% saline,
mitozolomide was suspended in arachis oil and MeCCNU
was dissolved in 10% ethanol/arachis oil. The concentrations
were such that the required dose could be administered in
0.1 ml per 1Og body weight. All injections were i.p.
Chemotherapy
Tumour bearing animals were allocated by restricted ran-
domisation into groups of 10. With the more rapidly grow-
ing MAC 13, MAC 15A and BML1 tumours, chemotherapy
commenced 2 days after implantation. MAC 13 tumours are
palpable at this stage and anti-tumour responses were
assessed 14 days later by recording tumour weights.
MAC 15A and BML1 tumours were assessed from median
survival times (MST) (Geran et al., 1972). With the slower
growing MAC 16 and MAC 26 tumours, chemotherapy did
not commence until tumours could be reliably measured i.e.
until they achieved minimum tumour dimensions of
4 x 5mm. Therapeutic effects were assessed by twice weekly,
two dimensional caliper measurements of the tumour.
Tumour volume was calculated from the formula a2 x b/2,
where a is the smaller diameter and b is the larger (Geran et
al., 1972). Tumour volumes were normalised with respect to
starting volumes and graphs of the relative tumour volume
against time were plotted on semi-log graph paper. The most
active agent against each specific tumour line was used as
positive control compound.
Toxicity
Whilst peripheral blood cell counts give an indication of
bone marrow damage they give no measure of the severity of
the damage or the recovery potential of haemopoietic tissues
(Schofield, 1986). It is therefore necessary to record bone
marrow damage as well as effects on peripheral blood
counts.
Haemopoietic effects
1. Peripheral blood counts.
Blood samples were obtained from the tail vein using
20pk accupets (Coulter Electronics Limited) at various
time intervals after i.p. inoculation of mitozolomide.
Erythrocyte and leucocyte counts were carried out on a
Coulter Counter Model D (Coulter Electronics Limited)
and platelets were counted using an improved Neu-
bauer chamber (Dacie & Lewis, 1984).
2. Spleen colony forming units (CFU-S)
The effects of mitozolomide on the bone marrow were
assayed by the spleen colony forming unit method of
Till & McCulloch (1961). The mice were exposed to X-
irradiation from a Newton Victor Superficial Therapy
Unit (GXIO) at a dose of 11.7Gy. They were subse-
quently injected i.v. via the tail vein with 1 x 105
marrow cells either from control mice or from mice
which had been treated 24h previously with mitozolo-
mide. Eight days later the mice were killed, the spleens
removed and fixed in Bouin's fluid and the nodules
which can readily be seen on the spleen were counted.
Testicular toxicity
Groups of 5, 10-week old male NMRI mice were sacrificed
at 5, 22, 32, 42 and 53 days after i.p. injection of mitozolo-
mide (37.5 mgkg-1), thioTEPA (20mgkg-1) and MeCCNU
(15 mgkg-1). These are maximum tolerated single doses for
these drugs in male mice of this age. At levels in excess of
these, animals die from a combination of gastrointestinal
and haematological toxicity. ThioTEPA and MeCCNU were
selected as positive control compounds because thioTEPA is
highly toxic in this system (Wahed et al., 1987) and
MeCCNU has a similar mechanism of action to mitozolo-
mide. The testes were removed and weighed, either fixed
with Bouin's fluid and then subjected to routine histological
processing, or placed in distilled water, homogenised and
sonicated for sperm head counts (Meistrich et al., 1978).
Sections of fixed material were cut at 5gm and stained with
haemotoxylin and eosin (H&E) or periodic acid-Schiff
(PAS). Seminiferous tubule diameter was measured by means
of an ocular micrometer.
Ovarian toxicity
Groups of 6, 7-week old female mice were sacrificed at 2, 20,
40 and 60 days after a single i.p. injection of mitozolomide
(37.5 mgkg-1), MeCCNU (25 mgkg-1) or cyclophospha-
mide (300 mgkg-1). These are maximum tolerated doses in
female mice at this age. Cyclophosphamide and MeCCNU
were selected as positive control compounds as cyclophos-
phamide has been shown to be highly toxic in this system
(Abu-Khalaf et al., 1987) and MeCCNU is thought to have
a similar mechanism of action to mitozolomide. Ovaries were
removed, fixed in Bouin's fluid and 5ym serial sections were
stained with H&E. Oocytes were classified into 6 stages of
follicular development and whether they were atretic or
normal. After completion of counts from every 20th section
the total number of follicles per ovary was determined (Abu-
Khalaf et al., 1987).
Results
Anti-tumour activity
Anti-tumour responses were achieved with mitozolomide at
maximum tolerated dose (37.5 mgkg-1) against BML1,
MAC 13, MAC 15A and MAC26 (Table I). These responses
were in the same order as those produced by the appropriate
positive control compound for each tumour line. No signifi-
cant responses were achieved below this dose level except for
MAC 13 which is responsive to chloroethylating agents.
MAC 16 was unresponsive to mitozolomide.
Toxicity
In acute toxicity studies where the mice die from a combi-
nation of gastrointestinal and haematological toxicity the
LD10 dose of mitozolomide was found to be 45 +3mgkg-1
(mean+s.e.m.). Maximum tolerated dose was estimated as
37.5 mgkg1.
Haemopoietic toxicity
1. Peripheral blood counts: Single i.p. injection of mito-
zolomide at maximum tolerated dose had no effect on
peripheral blood erythrocyte count (Figure la). Leuco-
cyte counts were depleted on day 4 (P<0.01) (Figure
lb). Platelet counts were significantly depressed
(P<0.01) on days 7, 11 and 14 (Figure lc).
2. Spleen colony forming unit (CFU-S assay): The effects
of mitozolomide on CFU-S are described in Table II.MITOZOLOMIDE - ANTI-TUMOUR ACTIVITY AND TOXICITY
Table I Anti-tumour activity of mitozolomide
Dose TIC Inhibition Positive control TIC Inhibition
Tumours Evaluation (mgkg 1) (%) (%) compound (%) (%)
BML 1 MST 37.5 180 - MeCCNU 200
MAC 13 Tumour weight 37.5 0.07 >99
25 0.45 55 MeCCNU 0.66 >99
MAC 15A MST 37.5 172 MeCCNU 164
MAC 16 Growth delay/ 50 Toxic - None
Tumour volumes 37.5 - 0
MAC 26 Growth delay/ 50 Toxic - 5-FU 45 55
Tumour volumes 37.5 40 60
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Testicular toxicity
The effects of mitozolomide and positive control compounds
on testis weight are presented in Figure 2. There was a
significant decrease in testicular weight following treatment
at maximum tolerated dose with both mitozolomide and
thioTEPA. MeCCNU had no significant effect on testis
weight.
Examination of tissue sections revealed a significant
decrease (P<0.01) in the diameter of seminiferous tubules in
mice treated with mitozolomide and thioTEPA at 22 and 32
days after injection (Figure 3). These changes were accompa-
nied by a depletion in spermatogonia, spermatocytes and
early spermatids resulting in a decrease in germinal epithelial
size (Figure 4). No significant changes in these parameters
were seen following MeCCNU treatment. Sperm head counts
revealed a significant depression (P<0.01) following mito-
zolomide and thioTEPA treatment (Figure 5). MeCCNU did
not produce a significant depression in sperm head count.
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Figure 1 Effects of a single i.p. dose of mitozolomide
(40mgkg-1) (0-0) on peripheral blood cell counts: (a)
erythrocytes, (b) leucocytes, (c) platelets. Mean values +s.e.m.
Untreated controls, *-*.
Table II Effects of mitozolomide on spleen colony forming units
(CFU-S)
Donor Recipient
Dose Radiation No. bone marrow
Treatment (mgkg 1) (Gy) cells injected CFU-Sa
- - 11.7 1.2 x 105 40
Mitozolomide 20 11.7 1.0 x 105 4
Mitozolomide 30 11.7 9.0 x 104 3
Mitozolomide 40 11.7 1.0x 105 0
aMean of 6 individual mice in each group.
Following inoculation of 1.2 x 105 bone marrow cells in
normal irradiated mice, 40 colonies were seen in the
spleen. Treatment of donor mice with a dose of
40mgkg-1 mitozolomide resulted in complete destruc-
tion of CFU-S in recipient mice. Lower doses of
mitozolomide resulted in approximately a 10-fold
reduction in CFU-S compared to control mice.
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Figure 2 The effects of mitozolomide (@---), methylCCNU
(U-*) and thioTEPA (A-A) at maximum tolerated doses on
mouse testis weight.
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Figure 3 The effects of mitozolomide (@---), methylCCNU
(- *) and thioTEPA (A-A) at maximum tolerated doses on
diameter of seminiferous tubules.
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Ovarian toxicity
The effects of single i.p. injection of mitozolomide,
MeCCNU and cyclophosphamide at maximum tolerated
doses are presented in Figure 6. The data are presented
graphically as a logarithmic regression computer plot using
data accumulated over the first 60 days and extrapolated to
140 days. There was continuous depletion of all stages of
oocytes. The depletion of oocytes was most marked with
mitozolomide and oocyte count was least affected by
MeCCNU.
Discussion
The anti-tumour responses seen with mitozolomide in the
panel of tumours used in this study are similar to those seen
with MeCCNU. Good responses were seen against MAC 13
but the dose response curve is steep and the therapeutic
index (LD50/ID90) is still less than 2. The well-differentiated
cystic MAC26 shows only a modest response to mitozolo-
mide and is unresponsive to MeCCNU. The well-
differentiated MAC 16 adenocarcinoma which produces
severe body wasting in the host (Bibby et al., 1987) is
unresponsive to both mitozolomide and MeCCNU. Res-
ponses in the other tumour lines are only achieved near to
maximum tolerated dose. These responses can only be
achieved at the expense of severe host toxicity. Haemopoietic
toxicity is clearly demonstrated by analysis of peripheral
blood counts and also by the CFU-S assay. Even though the
Figure
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4 Normal mouse testis (a) and appearance 22 days after reduction in platelet count was only to 25% of normal
nt with mitozolomide (40mgkg-1) (b). Sections stained values the CFU-S assay clearly shows that at doses necessary
&B. to achieve anti-tumour effects the bone marrow is irreversi-
bly damaged. In addition to haemopoietic toxicity in this
study, we have clearly demonstrated significant toxic effects
on reproductive tissues. Mitozolomide caused severe testis
weight loss, a decrease in seminiferous tubule diameter and
considerable epithelial damage. These effects are accompa-
nie.d hv a sienificnnt dronn in snerm counts Testicuilar
damage was similar to that produced by thioTEPA and the
effects were considerably worse than those seen with
MeCCNU.
The study has also demonstrated severe oocyte toxicity.
Mitozolomide was the most potent of the 3 agents tested
here, with oocyte numbers falling to 50% of control values
in 15 days. These results on reproductive tissues suggest that
if mitozolomide was to proceed to general clinical use,
significant reproductive effects would be seen in patients. I -- --Jr , -- -- r-v- --
0 30 60 Mitozolomide is an example of a novel anti-cancer drug
Days which showed exciting activity in experimental tumour
systems but went on to behave disappointingly in the clinic 5)anthioTEef
of
-A) mitoomaxide u t)olmerathyCCNU on due to severe toxicity. As with other standard cytotoxic
head count in mouse testism agents it was selected using pre-clinical test systems where
*iead count in mouse testis. chemosensitivity does not clearly reflect that of clinical
tumours. The current policy of the Cancer Research
t-ampaign rnase I Clinical Irial Committee is to iodentuiy
and progress novel compounds through to clinical trial as
rapidly as possible (Connors, 1985). In pre-clinical toxicity
studies organ specific toxicity is only determined retro-
spectively should any untoward clinical symptoms appear
(Fox, personal communication). The present study has
demonstrated clearly that it is possible to predict severe
toxicities in an appropriate experimental test system in
parallel with anti-tumour studies. By including simple bioas-
says of specific organ toxicity similar to those described in
this paper it should be possible to recommend the most
appropriate members of new series of active agents to go
forward for early clinical evaluation. In order to do this it is
clearly necessary to use model tumour systems that are
Days similar in sensitivity to solid cancers in man where thera-
6 Comnarison between re2ression lines of totnal oncvte peutic indices are low.
counts on mice treated with (a) mitozolomide, (b) cyclophospha-
mide, (c) methylCCNU at maximum tolerated doses with
controls (d).
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